- Home
- DNP vs SWTX Comparison
DNP vs SWTX Comparison
Compare DNP & SWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNP
- SWTX
- Stock Information
- Founded
- DNP 1986
- SWTX 2017
- Country
- DNP United States
- SWTX United States
- Employees
- DNP N/A
- SWTX N/A
- Industry
- DNP Investment Managers
- SWTX Biotechnology: Pharmaceutical Preparations
- Sector
- DNP Finance
- SWTX Health Care
- Exchange
- DNP Nasdaq
- SWTX Nasdaq
- Market Cap
- DNP 3.4B
- SWTX 3.0B
- IPO Year
- DNP N/A
- SWTX 2019
- Fundamental
- Price
- DNP $9.45
- SWTX $58.25
- Analyst Decision
- DNP
- SWTX Strong Buy
- Analyst Count
- DNP 0
- SWTX 6
- Target Price
- DNP N/A
- SWTX $70.83
- AVG Volume (30 Days)
- DNP 708.8K
- SWTX 3.3M
- Earning Date
- DNP 01-01-0001
- SWTX 02-20-2025
- Dividend Yield
- DNP 8.63%
- SWTX N/A
- EPS Growth
- DNP N/A
- SWTX N/A
- EPS
- DNP N/A
- SWTX N/A
- Revenue
- DNP N/A
- SWTX $191,589,000.00
- Revenue This Year
- DNP N/A
- SWTX $3,475.18
- Revenue Next Year
- DNP N/A
- SWTX $81.60
- P/E Ratio
- DNP N/A
- SWTX N/A
- Revenue Growth
- DNP N/A
- SWTX 3417.33
- 52 Week Low
- DNP $8.09
- SWTX $28.21
- 52 Week High
- DNP $11.18
- SWTX $62.00
- Technical
- Relative Strength Index (RSI)
- DNP 56.40
- SWTX 70.71
- Support Level
- DNP $9.20
- SWTX $54.89
- Resistance Level
- DNP $9.49
- SWTX $62.00
- Average True Range (ATR)
- DNP 0.11
- SWTX 4.09
- MACD
- DNP -0.00
- SWTX 1.35
- Stochastic Oscillator
- DNP 78.12
- SWTX 85.90
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.